Calogero Lauricella
University of Turin
42 Papers
184 Citations
Calogero Lauricella is an academic researcher from University of Turin. The author has contributed to research in topics: KRAS & Medicine. The author has an hindex of 14, co-authored 30 publications.
Chat about Author
Papers
Detection of Circulating Tumor DNA in Early- and Late-Stage Human Malignancies
Chetan Bettegowda,Chetan Bettegowda,Mark Sausen,Rebecca J. Leary,Isaac Kinde,Yuxuan Wang,Nishant Agrawal,Nishant Agrawal,Bjarne Bartlett,Bjarne Bartlett,Hao Wang,Brandon Luber,Rhoda M. Alani,Emmanuel S. Antonarakis,Nilofer S. Azad,Alberto Bardelli,Henry Brem,John L. Cameron,Clarence Lee,Leslie A. Fecher,Leslie A. Fecher,Gary L. Gallia,Peter Gibbs,Dung T. Le,Dung T. Le,Robert L. Giuntoli,Michael Goggins,Michael D. Hogarty,Matthias Holdhoff,Seung-Mo Hong,Seung-Mo Hong,Yuchen Jiao,Hartmut Juhl,Jenny J. Kim,Giulia Siravegna,Daniel A. Laheru,Calogero Lauricella,Michael Lim,Evan J. Lipson,Suely Kazue Nagahashi Marie,George J. Netto,Kelly S. Oliner,Alessandro Olivi,Louise Olsson,Gregory J. Riggins,Andrea Sartore-Bianchi,Kerstin Schmidt,le-Ming Shih,Sueli Mieko Oba-Shinjo,Salvatore Siena,Dan Theodorescu,Jeanne Tie,Timothy T. Harkins,Silvio Veronese,Tian Li Wang,Jon D. Weingart,Christopher L. Wolfgang,Laura D. Wood,Dongmei Xing,Ralph H. Hruban,Jian Wu,Peter J. Allen,C. Max Schmidt,Michael A. Choti,Victor E. Velculescu,Kenneth W. Kinzler,Bert Vogelstein,Nickolas Papadopoulos,Luis A. Diaz,Luis A. Diaz +69 more
TL;DR: The ability of circulating tumor DNA (ctDNA) to detect tumors in 640 patients with various cancer types was evaluated and suggested that ctDNA is a broadly applicable, sensitive, and specific biomarker that can be used for a variety of clinical and research purposes.
Clonal evolution and resistance to EGFR blockade in the blood of colorectal cancer patients
Giulia Siravegna,Benedetta Mussolin,Michela Buscarino,Giorgio Corti,Andrea Cassingena,Giovanni Crisafulli,Agostino Ponzetti,Chiara Cremolini,Alessio Amatu,Calogero Lauricella,Simona Lamba,Sebastijan Hobor,Antonio Avallone,Emanuele Valtorta,Giuseppe Rospo,Enzo Medico,Valentina Motta,Carlotta Antoniotti,Fabiana Tatangelo,Beatriz Bellosillo,Silvio Veronese,Alfredo Budillon,Clara Montagut,Patrizia Racca,Silvia Marsoni,Alfredo Falcone,Ryan B. Corcoran,Federica Di Nicolantonio,Fotios Loupakis,Salvatore Siena,Andrea Sartore-Bianchi,Alberto Bardelli +31 more
TL;DR: The results indicate that the CRC genome adapts dynamically to intermittent drug schedules and provide a molecular explanation for the efficacy of rechallenge therapies based on EGFR blockade.
Dual-targeted therapy with trastuzumab and lapatinib in treatment-refractory, KRAS codon 12/13 wild-type, HER2-positive metastatic colorectal cancer (HERACLES): A proof-of-concept, multicentre, open-label, phase 2 trial
Andrea Sartore-Bianchi,Livio Trusolino,Cosimo Martino,Katia Bencardino,Sara Lonardi,Francesca Bergamo,Vittorina Zagonel,Francesco Leone,Ilaria Depetris,Erika Martinelli,Teresa Troiani,Fortunato Ciardiello,Patrizia Racca,Andrea Bertotti,Giulia Siravegna,Valter Torri,Alessio Amatu,Silvia Ghezzi,Giovanna Marrapese,Laura Palmeri,Emanuele Valtorta,Andrea Cassingena,Calogero Lauricella,Angelo Vanzulli,Daniele Regge,Silvio Veronese,Paolo M. Comoglio,Alberto Bardelli,Silvia Marsoni,Salvatore Siena +29 more
TL;DR: The combination of trastuzumab and lapatinib is active and well tolerated in treatment-refractory patients with HER2-positive metastatic colorectal cancer.
911
Assessment of a HER2 scoring system for colorectal cancer: results from a validation study
Emanuele Valtorta,Cosimo Martino,Andrea Sartore-Bianchi,Frédérique Penaullt-Llorca,Giuseppe Viale,Mauro Risio,Massimo Rugge,Walter F. Grigioni,Katia Bencardino,Sara Lonardi,Vittorina Zagonel,Francesco Leone,Johannes Noe,Fortunato Ciardiello,Carmine Pinto,Roberto Labianca,Stefania Mosconi,Claudio Graiff,Giuseppe Aprile,Barbara Frau,Carlo Garufi,Fotios Loupakis,Patrizia Racca,Giuseppe Tonini,Calogero Lauricella,Silvio Veronese,Mauro Truini,Salvatore Siena,Silvia Marsoni,Marcello Gambacorta +29 more
TL;DR: In a phase II trial of trastuzumab and lapatinib in a cetuximab-resistant population, HERACLES Diagnostic Criteria shaped the selection of patients and defined ERBB2 as a predictive marker for response to ER BB2-targeted therapy in metastatic colorectal cancer.
281
Blockade of EGFR and MEK Intercepts Heterogeneous Mechanisms of Acquired Resistance to Anti-EGFR Therapies in Colorectal Cancer
Sandra Misale,Sabrina Arena,Simona Lamba,Giulia Siravegna,Alice Lallo,Sebastijan Hobor,Mariangela Russo,Michela Buscarino,Luca Lazzari,Andrea Sartore-Bianchi,Katia Bencardino,Alessio Amatu,Calogero Lauricella,Emanuele Valtorta,Salvatore Siena,Federica Di Nicolantonio,Alberto Bardelli +16 more
TL;DR: The studies from Bettegowda and Misale and their colleagues show the effectiveness of analyzing circulating DNA from a variety of tumors and highlight the potential applications of this technology for early detection, monitoring resistance, and devising treatment plans to overcome resistance.